Triveni Bio, a clinical-stage biotechnology company advancing novel antibody treatments for immunological and inflammatory (I&I) disorders, announced a $65 million Series C financing round to support pipeline expansion and continued corporate growth. The round was co-led by new investors Ascenta Capital and Janus Henderson Investors, with significant participation from Deep Track Capital, alongside additional existing investors.